Core Insights - Aegon reported strong commercial momentum in key markets during the first half of 2025, with notable increases in new life sales and net deposits across various regions [5][6][9] - The company is on track to meet its Operating Capital Generation (OCG) guidance for 2025, with a significant operating result and a robust capital position [6][7][9] - Aegon announced a review for relocating its legal domicile and head office to the United States, reflecting its strategic focus on the U.S. market, which constitutes approximately 70% of its operations [8][10] Financial Highlights - New life sales in the U.S. increased by 13% to USD 276 million [5] - The operating result for the first half of 2025 was EUR 845 million, a 19% increase compared to the same period in 2024 [6][9] - Net profit reached EUR 606 million, a significant recovery from a net loss of EUR 65 million in the first half of 2024 [9] Capital Highlights - Aegon reported EUR 576 million in Operating Capital Generation (OCG) for the first half of 2025, maintaining its guidance of around EUR 1.2 billion for the year [6][9] - The company announced an interim dividend of EUR 0.19 per common share, reflecting a year-on-year increase of 19% [7][9] - Aegon is increasing its share buyback program to EUR 400 million, up from the previously announced EUR 200 million [7][9] Strategic Developments - Aegon is conducting a review on the potential relocation of its head office to the U.S., aiming to simplify its corporate structure and align its legal domicile with its primary market [8][10] - The review's outcome is expected to be shared at the Capital Markets Day on December 10, 2025 [10]